World Health Organization (2008) Global tuberculosis control: Surveillance, planning, financing. Available: http://www.who.int/tb/publications/globa？l_report/en/. Accessed 5 January 2009.
[2]
Jain A, Mondal R (2008) Extensively drug-resistant tuberculosis: Current challenges and threats. FEMS Immunol Med Microbiol 53: 145–150.
[3]
Iseman MD (1994) Evolution of drug-resistant tuberculosis: A tale of two species. Proc Natl Acad Sci U S A 91: 2428–2429.
[4]
World Health Organization (2008) Anti-tuberculosis drug resistance in the world. Fourth global report. Available: http://www.who.int/tb/publications/2008/？drs_report4_26feb08.pdf. Accessed 5 January 2009.
[5]
Ramaswamy S, Musser JM (1998) Molecular genetic basis of antimicrobial agent resistance in : 1998 update. Tuber Lung Dis 79: 3–29.
[6]
Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, et al. (2005) Towards a proteome-scale map of the human protein-protein interaction network. Nature 437: 1173–1178.
[7]
Uetz P, Giot L, Cagney G, Mansfield TA, Judson RS, et al. (2000) A comprehensive analysis of protein-protein interactions in . Nature 403: 623–627.
[8]
Hood L, Heath JR, Phelps ME, Lin B (2004) Systems biology and new technologies enable predictive and preventative medicine. Science 306: 640–643.
[9]
Rives AW, Galitski T (2003) Modular organization of cellular networks. Proc Natl Acad Sci U S A 100: 1128–1133.
[10]
Kerrien S, Alam-Faruque Y, Aranda B, Bancarz I, Bridge A, et al. (2007) IntAct—Open source resource for molecular interaction data. Nucleic Acids Res 35: D561–D565.
[11]
Xenarios I, Salwinski L, Duan XJ, Higney P, Kim SM, et al. (2002) DIP, the Database of Interacting Proteins: A research tool for studying cellular networks of protein interactions. Nucleic Acids Res 30: 303–305.
[12]
Liolios K, Mavromatis K, Tavernarakis N, Kyrpides NC (2008) The Genomes On Line Database (GOLD) in 2007: Status of genomic and metagenomic projects and their associated metadata. Nucleic Acids Res 36: D475–D479.
[13]
Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, et al. (2008) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 36: D13–D21.
[14]
Demeter J, Beauheim C, Gollub J, Hernandez-Boussard T, Jin H, et al. (2007) The Stanford Microarray Database: Implementation of new analysis tools and open source release of software. Nucleic Acids Res 35: D766–D770.
[15]
Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, et al. (2007) NCBI GEO: Mining tens of millions of expression profiles—Database and tools update. Nucl Acids Res 35: D760–D765.
[16]
Parkinson H, Kapushesky M, Shojatalab M, Abeygunawardena N, Coulson R, et al. (2007) ArrayExpress—A public database of microarray experiments and gene expression profiles. Nucl Acids Res 35: D747–D750.
[17]
Reddy TB, Riley R, Wymore F, Montgomery P, Decaprio D, et al. (2008) TB database: An integrated platform for tuberculosis research. Nucleic Acids Res 37: D499–D508. doi:10.1093/nar/gkn652.
[18]
Koenig R (2007) Tuberculosis. Few mutations divide some drug-resistant TB strains. Science 318: 901–902.
[19]
Morgan M, Kalantri S, Flores L, Pai M (2005) A commercial line probe assay for the rapid detection of rifampicin resistance in : A systematic review and meta-analysis. BMC Infect Dis 5: 62.
[20]
Ling D, Zwerling AA, Pai M (2008) GenoType MTBDR assays for diagnosis of multidrug-resistant tuberculosis: A meta-analysis. Eur Respir J 32: 1165–1174.
[21]
World Health Organization (2008) Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement. Available: http://www.who.int/tb/dots/laboratory/lp？a_policy.pdf. Accessed 5 January 2009.
[22]
Anthony R, Schuitema A, Bergval I, Brown T, Oskam L, et al. (2005) Acquisition of rifabutin resistance by a rifampicin resistant mutant of involves an unusual spectrum of mutations and elevated frequency. Ann Clin Microbiol Antimicrob 4: 9.
[23]
Zhou J, Dong Y, Zhao X, Lee S, Amin A, et al. (2000) Selection of antibiotic-resistant bacterial mutants: Allelic diversity among fluoroquinolone-resistant mutations. JInfect Dis 182: 517–525.
[24]
Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, et al. (1996) Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant isolates with known rpoB mutations. Antimicrob Agents Chemother 40: 2655–2657.
[25]
Williams DL, Spring L, Collins L, Miller LP, Heifets LB, et al. (1998) Contribution of rpoB mutations to development of rifamycin cross-resistance in . Antimicrob Agents Chemother 42: 1853–1857.
[26]
Qian L, Abe C, Lin TP, Yu MC, Cho SN, et al. (2002) rpoB genotypes of Beijing family isolates from East Asian countries. J Clin Microbiol 40: 1091–1094.
